DTBE in Guyana
Capital City: Georgetown
Area*:214,970 sq. km. (83,000 sq. mi.)
Population (est.), 2009*: 777,000
Estimated TB Incidence, 2010**: 111/100,000
Estimated TB Prevalence, 2010**: 115/100,000
Adult HIV Prevalence Rate, 2009***: 1.2%
Number of people living with HIV (PLHIV), 2009***: 5,900
Percent of tested TB patients who were HIV+, 2010**: 28%
**Source: WHO Global TB Control Report 2011
***Source: UNAIDS, Report on the Global AIDS Epidemic, 2010
Guyana has one of the highest tuberculosis (TB) burdens in South America, and TB prevalence has steadily risen over the past two decades. A dispersed and remote population presents difficulties in providing diagnostic and treatment services in much of the country. The Centers for Disease Control and Prevention’s Division of Tuberculosis Elimination (CC/DTBE) provides ongoing support to CDC/Global AIDS Program (GAP) Guyana for TB/HIV activities, including yearly planning of TB/HIV support, building laboratory capacity, assessing infection control policies and program performance, and providing technical assistance for TB/HIV to CDC/GAP Guyana and to the Ministry of Health (MOH).
Recent Accomplishments & Ongoing Collaborations
Program Strengthening and Epidemiology
Laboratory Strengthening Activities: CDC has provided technical assistance and support to the MOH to upgrade the National Reference Laboratory to Biosafety Level (BSL) III standards, expand access to TB laboratory diagnostics, and facilitate collaboration between Guyana and the Supranational Reference Laboratory in Mexico.
Multidrug-resistant TB (MDR TB), TB/HIV, and Other At-Risk Populations
HIV Counseling, Testing, and Care of TB Patients at Chest Clinics:CDC/DTBE led an international team to describe the epidemiology of HIV-associated TB and assess the extent to which MOH chest clinics had integrated HIV testing, referral, and care and treatment. The results indicated a high rate of HIV infection among TB patients and an ability to integrate high quality HIV-related interventions in resource limited settings, though the degree and quality of integration varied by site. A follow-up evaluation of TB/HIV collaboration at both chest clinics and anti-retroviral therapy (ART) clinics has been conducted, and analysis is underway.